We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Fucoidan (Brown Seaweed Sulfated Polysaccharide)
A sulfated polysaccharide from brown seaweed (kelp, wakame, mozuku) marketed for immunity, anti-cancer support, and longevity. The preclinical literature is enormous (immunomodulatory, antiviral, antitumor in cells and animals), but human evidence is sparse: one small RCT showing better flu-vaccine antibody responses in the elderly, plus a handful of small/uncontrolled cancer-adjunct studies. A genuinely interesting molecule that remains clinically unproven.
What the evidence says
Fucoidan doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2007–2026 with a typical study size of 118 participants.
Based on 38 studies · 1 meta-analysis · 17 RCTs · 118 total participants
Confidence
Moderate confidenceBy outcome
An enormous preclinical literature contrasts with sparse human data: one small RCT improved flu-vaccine antibody responses, while a systematic review found cancer evidence too thin to pool, keeping it emerging.
19 randomised trials
every one checked individually
Every randomised or controlled trial of Fucoidan indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Jul 2026
6 trials ongoing or recruiting · 11 completed on ClinicalTrials.gov
2 of the completed trials have posted results
Registered trials show research momentum for Fucoidan, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Oct 2026
Fucoidan is a family of sulfated polysaccharides found in the cell walls of brown seaweeds such as Fucus vesiculosus (bladderwrack), Undaria pinnatifida (wakame/mekabu), and various mozuku and kombu species.
Cell-culture and animal studies report immunomodulatory, antiviral, anti-inflammatory, antioxidant, anticoagulant, and antitumor activities. This laboratory work drives aggressive marketing for immune support, 'natural anticancer' adjunct use, gut health, and longevity. The honest clinical reality is far thinner.
The single strongest human study is a small randomized, placebo-controlled trial in which Mekabu fucoidan (300 mg/day for 4 weeks) improved antibody responses to seasonal influenza vaccine in elderly Japanese adults.
Beyond that, a 2022 systematic review of fucoidan as a cancer supplement found only four small studies (one RCT, three quasi-experimental, n≈118 total) and could not pool them or issue clinical guidance.
Longevity and gut claims rest on invertebrate (C. elegans) and rodent models, and the much-hyped anticancer activity is overwhelmingly in-vitro. Fucoidan structure — and therefore activity — varies enormously by seaweed source and extraction, so 'fucoidan' is not one standardized thing.
Bottom line: mechanistically rich, broadly safe at studied doses, but with genuinely limited human efficacy evidence.
Activates macrophages, NK cells and dendritic cells and modulates cytokine output in lab models; the one human RCT showed enhanced vaccine antibody responses.
Induces apoptosis, inhibits proliferation and angiogenesis in cancer cell lines and animal models — not established in humans.
Sulfated structure underlies anti-inflammatory, antioxidant and pro-healing effects reported in cell and animal wound models.
How Fucoidan works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid or use only with clinician oversight due to theoretical anticoagulant activity.
Not studied — avoid.
Check the source; bladderwrack fucoidan can contain iodine.
Fucoidan is a sulfated polysaccharide with heparin-like anticoagulant activity in vitro; theoretical additive bleeding risk — caution and clinician oversight.
Theoretical: immunostimulatory activity could counter immunosuppressive therapy; clinical relevance unestablished.
Fucus vesiculosus-derived fucoidan can carry iodine, which may affect thyroid function — relevant only for bladderwrack sources.
Tip: Take with food; reduce dose
Tip: Avoid with anticoagulants. Tell the surgical and anaesthetic team the exact product, dose and last dose well before an operation. Follow their instructions about stopping and restarting it.
Fucoidan has an evidence score of 3.5/10 — emerging evidence based on 38 indexed studies. A sulfated polysaccharide from brown seaweed (kelp, wakame, mozuku) marketed for immunity, anti-cancer support, and longevity. The preclinical literature is enormous (immunomodulatory, antiviral, antitumor in cells and animals), but human evidence is sparse: one small RCT showing better flu-vaccine antibody responses in the elderly, plus a handful of small/uncontrolled cancer-adjunct studies. A genuinely interesting molecule that remains clinically unproven. Representative study: PMID 35628061.
Dosing for Fucoidan: No established efficacy dose; the influenza-vaccine RCT used 300mg/day of Mekabu fucoidan — commercial products range widely (100-1000mg/day). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Fucoidan — consistent daily use matters more than the time of day. Taken with food in trials; no timing requirement is established.
Fucoidan has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include theoretical increased bleeding tendency, mild GI upset / diarrhea. How often they occur is not established for all of them. Use caution if any of these apply to you: Active bleeding disorders or upcoming surgery (theoretical anticoagulant activity); Pregnancy/breastfeeding (not studied).
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Lactoferrin
Too few graded studiesA multifunctional iron-binding glycoprotein from milk with broad antimicrobial, anti-inflammatory, and immune-modulating properties.
Beta-Glucans
Likely helpsPolysaccharides from yeast, mushrooms, or oats that train innate immune cells to respond faster to infections and pathogens.
Vitamin D3
Probably helpsHormone-like vitamin that regulates 1,000+ genes — deficiency is widespread and linked to poor immunity, depression, and bone loss.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 38 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research